Nurix Therapeutics (NRIX) EBIT Growth (3y) (2022 - 2026)
Powered by 
Analysis
Nurix Therapeutics (NRIX) EBIT Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -18.82% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 81.27% |
| 10 | Nurix Therapeutics | 2.86 Bn | 2.42 Bn | - | -52.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -52.11% |
| Feb 28, 2026 | -29.14% |
| Nov 30, 2025 | -19.50% |
| Aug 31, 2025 | -25.06% |
| May 31, 2025 | -1.87% |
| Feb 28, 2025 | -13.72% |
| Nov 30, 2024 | -19.43% |
| Aug 31, 2024 | -23.49% |
| May 31, 2024 | -22.49% |
| Feb 29, 2024 | -22.63% |
| Nov 30, 2023 | -31.34% |
| Aug 31, 2023 | -27.75% |
| May 31, 2023 | -26.47% |
| Feb 28, 2023 | -50.69% |
| Nov 30, 2022 | -53.11% |
| Aug 31, 2022 | -161.52% |